Viking Therapeutics
VKTX
114 hedge funds and large institutions have $77.3M invested in Viking Therapeutics in 2022 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 25 increasing their positions, 43 reducing their positions, and 42 closing their positions.
379% more call options, than puts
Call options by funds: $1.49M | Put options by funds: $311K
5.35% less ownership
Funds ownership: 39.61% → 34.26% (-5.3%)
19% less funds holding
Funds holding: 140 → 114 (-26)
42% less capital inflows, than outflows
Capital inflows: $15.9M | Capital outflows: $27.3M
42% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 43
57% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$6.54M |
| 2 |
Laurion Capital Management
New York
|
+$3.28M |
| 3 |
E
Ergoteles
New York
|
+$818K |
| 4 |
Morgan Stanley
New York
|
+$754K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$749K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$9.21M |
| 2 |
State Street
Boston,
Massachusetts
|
-$2.71M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.5M |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$1.29M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.22M |
VKTX Hedge Fund Activity: Q2 2022 in Review
114 of the 5,962 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q2 2022, worth a combined $77.3M — down 18% from $93.8M a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of VKTX and 18 opened new positions — a net loss of 24 holders — while 43 trimmed existing stakes and 25 added.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $6.54M. The largest seller was BlackRock, cutting an estimated $9.21M.
- 114 institutional investors held Viking Therapeutics (VKTX) as of Q2 2022, down from 140 in Q1 2022.
- Funds reported $77.3M of Viking Therapeutics stock for Q2 2022, down 18% quarter-over-quarter.
- 18 funds opened new Viking Therapeutics positions in Q2 2022 and 42 closed out, a net change of -24 holders.
- The largest Viking Therapeutics buyer in Q2 2022 was Balyasny Asset Management, an estimated $6.54M added.
- The largest Viking Therapeutics seller in Q2 2022 was BlackRock, an estimated $9.21M sold.
Based on aggregated 13F filings for Q2 2022.